TY - JOUR
T1 - Intra-articular injection of secretome, derived from umbilical cord mesenchymal stem cell, enhances the regeneration process of cartilage in early-stage osteoarthritis
T2 - an animal study
AU - Lubis, Andri Maruli Tua
AU - Aprianto, Petrus
AU - Pawitan, Jeanne Adiwinata
AU - Priosoeryanto, Bambang Pontjo
AU - Dewi, Tri Isyani Tungga
AU - Kamal, Achmad Fauzi
N1 - Funding Information:
This research is funded by the Ministry of Education, Culture, Research, and Technology, Republic of Indonesia (contract number 008/E4.1/AK.04.PRN/2021). The authors declare that they have no competing interests. Completed disclosure forms for this article following the ICMJE template are available on the article page, doi: 10.2340/17453674.2023.12359
Publisher Copyright:
© 2023 The Author(s).
PY - 2023
Y1 - 2023
N2 - Background and purpose—Mesenchymal stem cells (MSCs), both endogenous and exogenous, enhance chondrocyte proliferation by stimulating collagen type II. Secretome, an MSC derivate, has shown to also provide this mechanism through a paracrine effect. We aimed to evaluate the use of secretome and MSC in the management of early osteoarthritis (OA). Animals and methods—19 (1 control) male sheep (Ovies aries), which were operated on with total lateral meniscectomy to induce knee OA, were divided into 3 groups: the secretome group, hyaluronic acid group, and MSC group. Each group was injected with the respective substances and was evaluated macroscopically and microscopically. The Osteoarthritis Research Society International (OARSI) score was calculated for all subjects and a descriptive and comparative statistical analysis was undertaken. Results—The macroscopic analysis of the treated groups revealed better OARSI score in the secretome group compared with the other 2 groups. The secretome group showed a significantly better microscopic score compared with the hyaluronic acid group (mean difference [MD] 6.0, 95% confidence interval [CI] 0.15–12), but no significant difference compared with the MSC group (MD 1.0, CI–4.8 to 6.8). Conclusion—Intra-articular injection of secretome is effective in managing early-stage osteoarthritis in the animal model compared with hyaluronic acid and has similar efficacy to MSC injection.
AB - Background and purpose—Mesenchymal stem cells (MSCs), both endogenous and exogenous, enhance chondrocyte proliferation by stimulating collagen type II. Secretome, an MSC derivate, has shown to also provide this mechanism through a paracrine effect. We aimed to evaluate the use of secretome and MSC in the management of early osteoarthritis (OA). Animals and methods—19 (1 control) male sheep (Ovies aries), which were operated on with total lateral meniscectomy to induce knee OA, were divided into 3 groups: the secretome group, hyaluronic acid group, and MSC group. Each group was injected with the respective substances and was evaluated macroscopically and microscopically. The Osteoarthritis Research Society International (OARSI) score was calculated for all subjects and a descriptive and comparative statistical analysis was undertaken. Results—The macroscopic analysis of the treated groups revealed better OARSI score in the secretome group compared with the other 2 groups. The secretome group showed a significantly better microscopic score compared with the hyaluronic acid group (mean difference [MD] 6.0, 95% confidence interval [CI] 0.15–12), but no significant difference compared with the MSC group (MD 1.0, CI–4.8 to 6.8). Conclusion—Intra-articular injection of secretome is effective in managing early-stage osteoarthritis in the animal model compared with hyaluronic acid and has similar efficacy to MSC injection.
UR - http://www.scopus.com/inward/record.url?scp=85171127790&partnerID=8YFLogxK
U2 - 10.2340/17453674.2023.12359
DO - 10.2340/17453674.2023.12359
M3 - Article
AN - SCOPUS:85171127790
SN - 1745-3674
VL - 94
SP - 300
EP - 306
JO - Acta Orthopaedica
JF - Acta Orthopaedica
ER -